Bromo‐ and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) represents the majority of liver cancer and is the fourth most common cause of cancer‐related death. Although advances in molecular targeted therapy have shown promise, none of these agents has yet demonstrated significant clinical benefit. Bromo‐ and extraterminal dom...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Sci
Autores principales: Liu, Chen, Miao, Xiaolong, Wang, Yao, Wen, Liang, Cheng, Xiawei, Kong, Deqiang, Zhao, Pengwei, Song, Dandan, Wang, Xinyi, Ding, Xianfeng, Xia, Hongguang, Wang, Weilin, Sun, Qiming, Gong, Weihua
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2020
Materias:
Basic and Clinical Immunology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7540980/
https://ncbi.nlm.nih.gov/pubmed/32726482
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14588
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares